Bausch Health, a multinational specialty pharmaceutical company, completed the spin-off of its eye health business into an independent publicly traded entity Bausch + Lomb. "We are committed to taking action to unlock what we see as unrecognized value in Bausch Health shares, and we believe that separating our business into two highly focused, stand-alone companies is the way to accomplish that goal," Joseph C. Papa, Bausch Health Chairman and CEO.